5.8 C
Columbus
Saturday, November 23, 2024
More

    Licenses of 14 Patanjali Products Cancelled as Uttarakhand Authority Takes Action

    Read Later
    - Advertisement -

    The licensing authority in Uttarakhand has taken action by suspending the licenses of 14 Patanjali products manufactured by Patanjali’s Divya Pharmacy. This decision comes as a result of a case involving misleading advertisements.

    The banned products includes Drishti Eye drop, Swasari Gold, Swasari Vati, Bronchom, Swasari Pravahi, Swasari Avaleh and Mukta Vati Extra Power.

    It also includes Lipidom, Bp Grit, Madhugrit, Madhunashini Vati Extra Power, Livamrit Advance, Livogrit and Eyegrit Gold.

    - Advertisement -

    Supreme Court Hearing

    Image source: OIP.Bu8DBnQY2nENlB7AGrCBogHaDt (474×237) (bing.com)

    The Supreme Court is scheduled to hear the case regarding the apology by Yoga guru Ramdev and his associate Acharya Balkrishna on April 30.

    Both individuals will be present in court on Tuesday. During the previous hearing on April 23, the Supreme Court expressed dissatisfaction with Patanjali for not prominently displaying their apology in newspapers.

    The court questioned the size of the apology, comparing it to full-page advertisements for Patanjali products.

    Patanjali responded and stated that they had published an apology in 67 newspapers. They are emphasizing their respect for the court and their commitment to avoiding future mistakes.

    - Advertisement -

    Expanded Apology and Previous Actions on Patanjali

    Image source: OIP.xp3MzfLn-1RoQzoPUZ-NFQHaFj (474×355) (bing.com)

    Following the court’s order, Patanjali published a larger apology in newspapers. Prior to this, Ramdev and Balkrishna had tendered an “unconditional and unqualified apology” before the top court.

    The apology was regarding advertisements that made exaggerated claims about the effectiveness of Patanjali products like Coronil during the pandemic.

    Court’s Directives and IMA’s Plea

    Image source: Screenshot-2021-06-19-at-5.33.21-PM.jpg (555×298) (hillpost.in)

    In November 2023, the Supreme Court directed Patanjali to halt advertisements for products claiming to treat ailments and disorders which are listed in the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

    This directive came in response to a plea filed by the Indian Medical Association (IMA). IMA sought action against Ramdev for criticizing modern medicine.

    - Advertisement -

    With the suspension of licenses for 14 Patanjali products, the Supreme Court continues to address the case of the published apology by Ramdev and Balkrishna.

    This situation highlights the importance of responsible advertising and the need for companies to adhere to legal guidelines.

    The outcome of the court hearing will determine the next steps in addressing the issue of misleading advertisements and their impact on consumers.

    Website | + posts

    Mallika Sadhu is a journalist committed to revealing the raw, unfiltered truth. Mallika's work is grounded in a dedication to transparency and integrity, aiming to present clear and impactful stories that matter. Through comprehensive reporting and honest storytelling, she strives to contribute to provide narratives that genuinely inform and engage. When not dwelling in the world of journalism, she is immersed in the colors of her canvas and pages of her journal.

    - Advertisement -

    You May Like

    More Stories

    Related stories

    Breaking Menopause Taboos: Challenges Women Face in India

    In India, menopause is often shrouded in silence and...

    The ‘Loneliness’ Epidemic: Is Technology to Blame?

    In today's digital age, technology plays a major part...

    Science Astonishes: Know How Spaceflights Alter Human Body

    It is impossible to deny the fact that scientists’...

    FSSAI Ensures Fresh Food Deliveries with New Shelf Life Rule

    The Food Safety and Standards Authority of India (FSSAI)...

    Subscribe

    - Never miss a story with notifications

    - Gain full access to our premium content

    - Browse free from up to 5 devices at once

    Comments